Ads
related to: second generation parp inhibitor drugs
Search results
Results From The WOW.Com Content Network
PARP inhibitors are a call of drugs that are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP), which plays a role in repairing DNA in damaged cells. Medical uses of these drugs include the treatment of heritable cancers . [ 1 ]
Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. [3] It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer. [2]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...
Pamiparib is a member of the PARP inhibitor drug class. [ 1 ] In China, it is approved for the treatment of germline BRCA mutation -associated recurrent advanced ovarian , fallopian tube , and primary peritoneal cancers previously treated with two or more lines of chemotherapy.
Ads
related to: second generation parp inhibitor drugs